Arthur Sands
CEO, President & Director
Good evening, everyone. My name is Arthur Sands. I’m President and CEO of Nurix Therapeutics. And I’d like to welcome you to our 2025 Investor and Analyst event broadcasting here from Orlando, Florida after — well, still in the midst of a terrific ASH, but getting near the end, but a lot of exciting new information at ASH this year, not only for our programs, but many others that are relevant to the incredible opportunities to improve therapies for patients with CLL and many other diseases covered here. So really absolutely terrific meeting.
So we’re very excited to have you all tonight, and I’ll be making a few opening remarks, and then we’re going to dive — do a deep dive into our data that was presented here today. We’re very fortunate to have Dr. Alencar here from University of Miami, who will be presenting the data, a fantastic expert in the field, one of our key investigators. We’re very excited to have you. Thank you, Dr. Alencar. And then we’ll have our Chief Medical Officer, Paula O’Connor, talk to us about our development program for
Read the full article here